Puma Biotechnology (PBYI) EBIAT (2017 - 2025)
Puma Biotechnology (PBYI) has disclosed EBIAT for 9 consecutive years, with $13.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 30.34% year-over-year to $13.4 million, compared with a TTM value of $31.7 million through Dec 2025, up 4.71%, and an annual FY2025 reading of $31.1 million, up 2.75% over the prior year.
- EBIAT was $13.4 million for Q4 2025 at Puma Biotechnology, up from $9.1 million in the prior quarter.
- Across five years, EBIAT topped out at $20.3 million in Q3 2024 and bottomed at -$44.7 million in Q3 2021.
- Average EBIAT over 5 years is $3.4 million, with a median of $5.0 million recorded in 2021.
- The sharpest move saw EBIAT surged 1703.61% in 2023, then crashed 442.61% in 2024.
- Year by year, EBIAT stood at $4.3 million in 2021, then skyrocketed by 69.77% to $7.3 million in 2022, then surged by 69.51% to $12.3 million in 2023, then surged by 56.83% to $19.3 million in 2024, then crashed by 30.34% to $13.4 million in 2025.
- Business Quant data shows EBIAT for PBYI at $13.4 million in Q4 2025, $9.1 million in Q3 2025, and $6.2 million in Q2 2025.